Roivant Sciences Ltd. (ROIV) shares tumbled 6.11% in pre-market trading on Monday following the release of its second-quarter financial results for the period ended September 30, 2025. The biopharmaceutical company reported disappointing earnings and revenue figures that fell short of analyst expectations.

The company posted a quarterly loss of $0.17 per share, which was narrower than the $0.33 loss per share anticipated by analysts. However, Roivant's revenue for the quarter came in at a mere $1.571 million, significantly below the FactSet estimate of $5.6 million. The company's income from operations also missed the mark, reporting a loss of $306.233 million compared to the expected loss of $277.8 million.

Despite the disappointing financial results, Roivant highlighted some positive developments in its business update. The company reported progress in its brepocitinib program, with favorable results in a Phase 3 study for dermatomyositis. Additionally, Roivant maintained a strong cash position of $4.4 billion as of September 30, 2025, which it claims will support its cash runway into profitability. However, these positives were not enough to offset investor concerns about the company's current financial performance, leading to the significant pre-market decline.